...
首页> 外文期刊>Drug discovery today >Drug-induced arrhythmias and sudden cardiac death: implications for the pharmaceutical industry
【24h】

Drug-induced arrhythmias and sudden cardiac death: implications for the pharmaceutical industry

机译:药物性心律失常和心源性猝死:对制药行业的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Following a series of high profile withdrawals from the market, the ability of medications to induce potentially fatal arrhythmias is a significant problem facing the pharmaceutical industry. Current preclinical cardiac safety assays are based on the assumption that blockade of a single repolarizing K+ channel alone precipitates drug-induced arrhythmias, however, current findings point to a range of more complex arrhythmogenic mechanisms. This review begins by exploring clinical findings and potential mechanisms underlying drug-induced sudden cardiac death and then goes on to assess current and explore future strategies to detect cardiotoxicity at the preclinical stage.
机译:在一系列高调退出市场后,药物引起潜在致命性心律失常的能力成为制药行业面临的重大问题。当前的临床前心脏安全性测定基于这样一个假设,即仅单个单个极化K +通道的阻滞会引起药物诱发的心律失常,但是,目前的发现指向一系列更复杂的心律失常机制。这篇综述首先探讨了临床发现和药物诱发的心源性猝死的潜在机制,然后继续评估了当前的情况,并探讨了在临床前阶段检测心脏毒性的未来策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号